SK Biopharmaceuticals stock
326030.KSKSCSK Biopharmaceuticals Co., Ltd., HealthcareISIN KR7326030004
67Score 67 out of 100, Neutral
Price and trend
58 / 100
Price history
−31% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 4.5% below it.
Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 72).
The price is 38% below its 52-week high. Largest decline in 6 years: 76% (July 2020 to October 2022).
Chart figures for advanced users
- SMA 50$59.30
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$68.72
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)72
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$52.02
- The lowest closing price of the last twelve months.
- Resistance$105.46
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- SK Biopharmaceuticals Co., Ltd. belongs to the Biotechnology industry (South Korea) and, with a market value of $5.14B, is number 73 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $529.75M (up 29.1% year on year) and earnings of $200.1M (up 10.9%).
- For fiscal 2026, analysts expect on average revenue of $730.52M (up 37.9%) and adjusted earnings per share of $3.01 (up 19.7%).
Show more
- MEQIRI Score 67 out of 100 (Neutral): rank 174 of 702 in Healthcare, median 53.
- The P/E is 18 (Biotechnology median 45.8, own median of recent years 36.6).
- Our model puts fair value at $115.43, with the price 43% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 93.6% a year since 2020, Biotechnology median 19.7%.Growth 70
- High marginNet margin 41.1% over the last 12 months, Biotechnology median 13%.Profitability 99
- High return on capitalReturn on invested capital 40.8% in fiscal 2025, Biotechnology median 4.9%.Profitability 99
Weaknesses
- Volatile share priceVolatility 48% a year over the last 12 months.
Its standout strengths are profitability and stability, while fundamentals and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 66 to 67.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $82.45 and expensive above $192.38 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $63.80 (cash-flow model) and $167.05 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $110.29, at 8.3% it would be $122.69.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (45.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 37.4% on the twelve months before. Revenue has grown strongly since 2018, at around 152% per year. From 2018 revenue only includes continuing operations, sold or discontinued divisions have been reclassified. Earlier years are not comparable and not shown, and the margins for 2018 are not measured.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 92%, operating 29%, net 38%. From 2018 revenue only includes continuing operations, sold or discontinued divisions have been reclassified. Earlier years are not comparable and not shown, and the margins for 2018 are not measured.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 10 Feb 2027in 89 days
- Last reported
- 5 Nov 2026EPS reported $0.58 (expected $0.58)in line with expectations
What happened at SK Biopharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 67
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Shanghai Allist Pharmaceuticals688578.SS $5.61B66
- ErascaERAS $5.52B44
- PTC TherapeuticsPTCT $5.29B46
- Dianthus TherapeuticsDNTH $5.21B46
- Cogent BiosciencesCOGT $5.07B28
- Travere TherapeuticsTVTX $4.95B50
- Edgewise TherapeuticsEWTX $4.93B54
- Adaptive BiotechnologiesADPT $4.77B47
ETFs that hold SK Biopharmaceuticals
Held by 21 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.22% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.19% | 0.40% | €813.42M |
| Franklin FTSE Korea UCITS ETFFLXK | 0.17% | 0.09% | €3.93B |
Show 5 more
| iShares MSCI EM Small Cap UCITS ETFEUNI | 0.11% | 0.74% | €279.38M |
| State Street SPDR MSCI Emerging Markets Small Cap UCITS ETFSPYX | 0.10% | 0.55% | €528.3M |
| Vanguard FTSE Developed Asia Pacific ex Japan UCITS ETF (USD) DistributingVGEJ | 0.04% | 0.15% | €2.61B |
| Franklin FTSE Asia ex China ex Japan UCITS ETFFVSJ | 0.03% | 0.14% | €547.95M |
| iShares MSCI EM IMI Screened UCITS ETF USD (Acc)AYEM | 0.02% | 0.18% | €5.26B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₩1,334.10)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 12 Dec 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.